Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Concert Pharmaceuticals, Inc. - Common Stock (NQ: CNCE )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 8.300 (1)
Ask (Size) 9.000 (6)
Prev. Close 8.370
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 32,173,778
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
From Concert Pharmaceuticals, Inc.
Via Business Wire
CNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire

Performance

More News

Read More
Why Concert Pharmaceuticals Stock Rocketed Higher This Week
Via The Motley Fool
CONCERT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Concert Pharmaceuticals, Inc. - CNCE
From Kahn Swick & Foti, LLC
Via Business Wire
India-Based Sun Pharma Scoops Up Concert Pharmaceuticals For $576M Plus Milestones
Via Benzinga
Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Concert Pharmaceuticals, Coeur Mining And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Concert Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Concert Pharma: Q3 Earnings Insights
Via Benzinga
Dow Falls 200 Points; Jobless Claims Drop To 4-Month Low
Via Benzinga
CNCE Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata
From Concert Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Is Ardelyx is A Buy After Slip in Early 2022
Via MarketBeat
Exposures Product Safety
Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research
From Concert Pharmaceuticals, Inc.
Via Business Wire
Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference
From Concert Pharmaceuticals
Via Business Wire
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results
From Concert Pharmaceuticals, Inc.
Via Business Wire
Concert Pharmaceuticals to Report Third Quarter 2022 Results on November 7, 2022
From Concert Pharmaceuticals, Inc.
Via Business Wire
Planet Labs, Core & Main And Some Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Breaking Session at EADV Congress
From Concert Pharmaceuticals, Inc.
Via Business Wire
Concert Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
From Concert Pharmaceuticals, Inc.
Via Business Wire
Bridges and Landmarks Across the USA Will Illuminate Blue Throughout the Month of September for Alopecia Areata
From Concert Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.